RPLP0

Across TCGA pan-cancer cohorts, RPLP0 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPLP0 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPLP0 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPLP0 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and GBM are the cancer types where RPLP0 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.918	0.664	.003	33	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	17	view →
GBM	DFS	Tertile	All	0.252	0.452	.007	6	view →
UCEC	DFS	Median	II,III,IV	0.505	0.877	.018	4	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	4	view →
LUAD	DFS	Median	All	0.982	0.818	.008	3	view →
LSCC	OS	Median	II,III,IV	0.882	0.626	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPLP0–HNSC (DFS)

Open the HNSC breakdown →